BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9279354)

  • 21. [A dose-comparative study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
    Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):477-94. PubMed ID: 7887640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can endocrine treatment for hormone-positive premenopausal women with early breast cancer replace adjuvant chemotherapy?
    Malayeri R
    J Clin Oncol; 2003 Jun; 21(12):2444-5; author reply 2446-7. PubMed ID: 12805348
    [No Abstract]   [Full Text] [Related]  

  • 23. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
    Schmid P; Untch M; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Lehmann U; Maubach L; Meurer J; Wallwiener D; Possinger K
    J Clin Oncol; 2007 Jun; 25(18):2509-15. PubMed ID: 17577027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A case of pleural and mediastinal lymph node metastases from breast cancer effectively treated with fadrozole hydrochloride in combination with cyclophosphamide].
    Kokufu I; Kim YH; Peng YF; Fukuda K; Yamamoto M; Yano T; Yamada K; Kitano H
    Gan To Kagaku Ryoho; 1999 Feb; 26(3):377-9. PubMed ID: 10065105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A case of breast cancer with multiple metastases successfully treated by medroxyprogesterone acetate with intermittent intra-arterial infusion low-dose chemotherapy to hepatic metastasis].
    Kusama M; Kaise H; Nakayama S; Oota D; Shimizu H; Aoki T; Koyanagi Y
    Gan To Kagaku Ryoho; 2000 Dec; 27(14):2243-7. PubMed ID: 11142170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
    J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant therapy for premenopausal patients with early breast cancer.
    Kurebayashi J
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):51-4. PubMed ID: 18197006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LH-RH agonists offer very good protection against the adverse gynaecological effects induced by tamoxifen.
    Berlière M; Galant C; Marques G; Piette P; Duck L; Fellah L; Donnez J; Machiels JP
    Eur J Cancer; 2004 Aug; 40(12):1855-61. PubMed ID: 15288287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea.
    Kim HJ; Lee JS; Park EH; Lim WS; Sei JY; Koh BS; Son BH; Ahn JH; Jeong KH; Kim SB; Ahn SH
    Eur J Surg Oncol; 2009 Sep; 35(9):936-41. PubMed ID: 19269125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hormone therapy for breast cancer].
    Saito Y; Suzuki Y; Tokuda Y
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():543-8. PubMed ID: 17682208
    [No Abstract]   [Full Text] [Related]  

  • 31. Luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer.
    Tanaka K; Tokunaga E; Yamashita N; Taketani K; Akiyoshi S; Morita M; Maehara Y
    Surg Today; 2014 Sep; 44(9):1678-84. PubMed ID: 24218007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Goserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal women.
    Jonat W
    Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):1-5. PubMed ID: 11900209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group.
    de Haes H; Olschewski M; Kaufmann M; Schumacher M; Jonat W; Sauerbrei W;
    J Clin Oncol; 2003 Dec; 21(24):4510-6. PubMed ID: 14610048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aromatase inhibitors with or without luteinizing hormone-releasing hormone agonist for metastatic male breast cancer: report of four cases and review of the literature.
    Kuba S; Ishida M; Oikawa M; Nakamura Y; Yamanouchi K; Tokunaga E; Taguchi K; Esaki T; Eguchi S; Ohno S
    Breast Cancer; 2016 Nov; 23(6):945-949. PubMed ID: 26879549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
    Sverrisdottir A; Nystedt M; Johansson H; Fornander T
    Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
    J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer].
    Ito T; Aizawa T; Yamamoto S; Ohkubo Y; Tsujino S; Miki M
    Hinyokika Kiyo; 1998 Jul; 44(7):477-80. PubMed ID: 9752601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
    Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
    Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormonal therapy for advanced breast cancer.
    Rugo HS
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.